Shots:
- MatOrtho has reported the European CE Mark approval of ReCerf for hip resurfacing arthroplasty, allowing wider availability in UK, EU & markets accepting CE mark approval
- ReCerf was previously approved by Australia’s TGA in Nov 2024 & was used in over 1,600 pts since 2018, with highly positive patient-reported outcomes & a low 6yr. revision rate
- ReCerf is a resurfacing implant made from Biolox delta ceramic, which prevents issues associated with metal-on-metal bearings & preserves more natural bone in pts
Ref: PRNewswire | Image: MatOrtho | Press Release
Related News:- Neurizon Therapeutics Licenses Monepantel from Elanco Animal Health to Accelerate NUZ-001 Commercialization
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
